Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

Carna Announces Upcoming Poster Presentation of Preliminary Results from Ongoing Phase 1b Study of Docirbrutinib, a Non-covalent Pan-mutant BTK Inhibitor, at the European Hematology Association Congress (EHA) 2025

FY2025 Q1 Presentation

Consolidated Financial Results for the First Quarter of the Year Ending December 31, 2025

Carna presented a poster on monzosertib at AACR Annual Meeting

Carna announces an upcoming poster presentation at AACR Annual Meeting

Carna Announces to Extend the Agreement with Sumitomo Pharma on Joint Research, Development, and Commercialization of Kinase Inhibitors

Corporate Presentation Feb. 2025

FY2024 Presentation